|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/498 | (2006.01) |
| A61K 31/4985 | (2006.01) | ||
| A61K 31/5025 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 43/00 | (2006.01) |
| (11) | Number of the document | 3122358 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15721129.3 |
| Date of filing the European patent application | 2015-03-26 | |
| (97) | Date of publication of the European application | 2017-02-01 |
| (45) | Date of publication and mention of the grant of the patent | 2020-12-16 |
| (46) | Date of publication of the claims translation | 2021-04-12 |
| (86) | Number | PCT/EP2015/056512 |
| Date | 2015-03-26 |
| (87) | Number | WO 2015/144804 |
| Date | 2015-10-01 |
| (30) | Number | Date | Country code |
| 14161835 | 2014-03-26 | EP |
| (72) |
JOVCHEVA, Eleonora, BE
PERERA, Timothy Pietro Suren, BE
|
| (73) |
Astex Therapeutics Ltd.,
436 Cambridge Science Park Milton Road, Cambridge CB4 0QA,
GB
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | EGFR ir CMET inhibitorių deriniai, skirti vėžio gydymui |
| COMBINATIONS OF FGFR- AND CMET-INHIBITORS FOR THE TREATMENT OF CANCER |
| Payment date | Validity (years) | Amount | |
| 2026-03-06 | 12 | 289.00 EUR |
| 2027-03-26 |